🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06597526
Recruiting Observational

The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.

NCT06597526 · tracked via the Priya Life Science China tracker
Sponsor
Ruijin Hospital
Phase
Observational
Started
2024-06-15
Last updated
2024-09-19

Condition(s) studied

Peritoneal MetastasisGastric Cancer

Study summary

This study aims to investigate the value of 18F-FDG\&68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Histologically confirmed gastric adenocarcinoma with no history of resection of primary or metastatic lesions 2. Peritoneal metastases of gastric cancer requiring laparoscopy for definitive diagnosis without gastric outflow tract obstruction and intestinal obstruction 3. Patients voluntarily enrolled in this study by signing an informed consent form 4. Age ≥ 18 years 5. Eastern Cooperative Oncology Group (ECOG) score ≤ 2, 6. Expected life expectancy ≥ 3 months 7. Adequate organ and bone marrow function 8. Willingness to adhere to the study protocol and follow-up programme Exclusion Criteria: 1. Signs of distant metastases other than peritoneal metastases at enrolment 2. Pregnant or breastfeeding women. 3. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix 4. Severe mental disease, uncontrolled epilepsy, or central nervous system disease

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine Shanghai Shanghai Municipality Recruiting

More Ruijin Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06597526 on ClinicalTrials.gov ↗ ← All trials in China